AIM
CAI

ARK Investment Management’s Caris Life Sciences CAI Stock Holding History

ARK Investment Management’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-408,725
Closed -$11M – 209
2025
Q4 		$11M Buy
408,725
+163,375
+67% +$4.6M 0.07% 107
2025
Q3 		$7.42M Buy
245,350
+198,300
+421% +$6.32M 0.04% 117
2025
Q2 		$1.26M Buy
+47,050
New +$1.27M 0.01% 166

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

ARK Investment Management's CAI Position: Q1 2026 in Review

ARK Investment Management sold out of Caris Life Sciences (CAI) in Q1 2026, closing a stake of 408,725 shares — an estimated $11M sold.

ARK Investment Management first reported a position in CAI in Q2 2025 and held it in 3 quarters. The position peaked at $11M in Q4 2025. 202 funds tracked by Wall St. Rank hold CAI as of Q1 2026.

  • ARK Investment Management reported no remaining Caris Life Sciences position as of Q1 2026 after selling out during the quarter.
  • ARK Investment Management sold 408,725 Caris Life Sciences shares in Q1 2026, an estimated $11M.
  • ARK Investment Management first reported a position in Caris Life Sciences in Q2 2025 and held it in 3 quarters.
  • ARK Investment Management's Caris Life Sciences position peaked at $11M in Q4 2025.
  • 202 funds tracked by Wall St. Rank held Caris Life Sciences as of Q1 2026.

Based on ARK Investment Management's 13F filing for Q1 2026, filed 12 May 2026.